Targeting Cancer with Benzimidazole Derivatives: Emerging Trends and Future Directions

Benzimidazole is a prominent nitrogen-containing heterocycle known for its broad utility across various fields, including agriculture, textile, and pharmaceuticals. Its unique electron rich structure and favorable chemical properties allow it to interact effectively with numerous biological targets. Benzimidazole derivatives are highly valuable due to their potential use in a broad spectrum of therapeutic treatments such as antimicrobial, antifungal, analgesic, antidiabetic, and anticancer treatments. Several drugs featuring the benzimidazole core, including Bilastine, Lerisetron, Maribavir, and Nocodazole, are already approved and used in clinical settings for indications such as allergies, viral infections, and cancer. Recently, anticancer agents like Binimetinib and Selumetinib—effective against BRAF-mutated melanoma and plexiform neurofibromas—have also received regulatory approval. Additionally, numerous benzimidazole-based candidates are currently undergoing advanced stages of clinical trials. Given the scaffold’s significant therapeutic promise, especially in oncology, it continues to attract the interest of medicinal chemists aiming to design novel, highly potent and target precise anticancer agents.